The Protein Purification Facility will leverage the cGMP compatible stable, non-lytic protein expression platform for expression of complex and challenging proteins, including Fab fragments and other proteins.
ExpreS2ion Biotechnologies CEO Dr. Charlotte Dyring said, "We have in the past used the ExpreS2 protein expression system to enable the advance of cancer projects, and this Research License confirms the relevance of the system in complementing existing protein needs in cancer research."
The license strengthens the company’s aim to make S2 as one of the standard protein production platforms in the fields of immunotherapy and therapeutic protein, according to ExpreS2ion Biotechnologies.
The Protein Purification Facility at the London Research Institute head Dr. Svend Kjaer said, "The technology complements our baculovirus-based protein expression activities perfectly and we look forward to expanding the application range of the technology to other projects involving other promising protein targets implicated in cancer."